scholarly journals Yogurt consumption and colorectal cancer incidence and mortality in the Nurses’ Health Study and the Health Professionals Follow-Up Study

2020 ◽  
Vol 112 (6) ◽  
pp. 1566-1575
Author(s):  
Karin B Michels ◽  
Walter C Willett ◽  
Rita Vaidya ◽  
Xuehong Zhang ◽  
Edward Giovannucci
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Cancer Incidence ◽  
Proximal Colon ◽  
Health Study ◽  
Follow Up Study ◽  
Incidence And Mortality ◽  
Colorectal Cancer Incidence ◽  
Colorectal Cancer Mortality

ABSTRACT Background Yogurt is a commonly consumed fermented food. Regular yogurt consumption may contribute to a favorable gut microbiome and gut health, but few epidemiologic studies have considered the relation between regular yogurt consumption and the incidence of and mortality from colorectal cancer. Objectives We used data from 2 large, prospective cohort studies, the Nurses’ Health Study and the Health Professionals Follow-Up Study, to examine the role of yogurt consumption on colorectal cancer incidence and mortality. Methods During 32 years of follow-up in 83,054 women (mean age at baseline, 45.7 years) and 26 years of follow-up in 43,269 men (mean age at baseline, 52.3 years), we documented a total of 2666 newly diagnosed cases of colorectal cancer in these cohorts. We modeled yogurt consumption at baseline and cumulatively updated it throughout follow-up. Results: Baseline yogurt consumption was associated with a reduced risk of colon cancer in age-adjusted analyses (P for trend < 0.001). Associations remained statistically significant after adjusting for potential confounders, including calcium and fiber intake (P for trend = 0.03), and were restricted to proximal colon cancer. The consumption of 1 + servings per week of yogurt at baseline, compared to no yogurt consumption, was associated with a multivariable HR of 0.84 (95% CI, 0.70–0.99; P trend = 0.04) for the proximal colon cancer incidence. Latency analyses suggested that the most important window of opportunity for regular yogurt consumption to prevent colorectal cancer was 16–20 years in the past. When yogurt consumption was cumulatively updated, associations attenuated and were no longer significant. No statistically significant inverse trend was observed between yogurt consumption and the colorectal cancer mortality. Conclusions In these large cohorts, the frequency of yogurt consumption was associated with a reduced risk of proximal colon cancer with a long latency period. No significant inverse trend was observed for colorectal cancer mortality.

scholarly journals Healthy lifestyle, endoscopic screening, and colorectal cancer incidence and mortality in the United States: A nationwide cohort study

PLoS Medicine ◽  
2021 ◽  
Vol 18 (2) ◽  
pp. e1003522
Author(s):  
Kai Wang ◽  
Wenjie Ma ◽  
Kana Wu ◽  
Shuji Ogino ◽  
Andrew T. Chan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Health Professionals ◽  
Healthy Lifestyle ◽  
The United States ◽  
Proximal Colon ◽  
Health Study ◽  
Endoscopic Screening ◽  
Incidence And Mortality

Background Healthy lifestyle and screening represent 2 major approaches to colorectal cancer (CRC) prevention. It remains unknown whether the CRC-preventive benefit of healthy lifestyle differs by endoscopic screening status, and how the combination of healthy lifestyle with endoscopic screening can improve CRC prevention. Methods and findings We assessed lifestyle and endoscopic screening biennially among 75,873 women (Nurses’ Health Study, 1988 to 2014) and 42,875 men (Health Professionals Follow-up Study, 1988 to 2014). We defined a healthy lifestyle score based on body mass index, smoking, physical activity, alcohol consumption, and diet. We calculated hazard ratios (HRs) and population-attributable risks (PARs) for CRC incidence and mortality in relation to healthy lifestyle score according to endoscopic screening. Participants’ mean age (standard deviation) at baseline was 54 (8) years. During a median of 26 years (2,827,088 person-years) follow-up, we documented 2,836 incident CRC cases and 1,013 CRC deaths. We found a similar association between healthy lifestyle score and lower CRC incidence among individuals with and without endoscopic screening, with the multivariable HR per one-unit increment of 0.85 (95% CI, 0.80 to 0.90) and 0.85 (95% CI, 0.81 to 0.88), respectively (P-interaction = 0.99). The fraction of CRC cases that might be prevented (PAR) by endoscopic screening alone was 32% (95% CI, 31% to 33%) and increased to 61% (95% CI, 42% to 75%) when combined with healthy lifestyle (score = 5). The corresponding PAR (95% CI) increased from 15% (13% to 16%) to 51% (17% to 74%) for proximal colon cancer and from 47% (45% to 50%) to 75% (61% to 84%) for distal CRC. Results were similar for CRC mortality. A limitation of our study is that our study participants are all health professionals and predominantly whites, which may not be representative of the general population. Conclusions Our study suggests that healthy lifestyle is associated with lower CRC incidence and mortality independent of endoscopic screening. An integration of healthy lifestyle with endoscopic screening may substantially enhance prevention for CRC, particularly for proximal colon cancer, compared to endoscopic screening alone.

scholarly journals Once-Only Sigmoidoscopy Screening for Colorectal Cancer: Incidence and Mortality Follow-up of the Italian Randomized Controlled Trial (SCORE)

2011 ◽  
Vol 140 (5) ◽  
pp. S-15 ◽  
Author(s):  
Nereo Segnan ◽  
Carlo Senore ◽  
Luigina A. Bonelli ◽  
Bruno Andreoni ◽  
Orietta Giliani ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Randomized Controlled Trial ◽  
Cancer Incidence ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Incidence And Mortality ◽  
Colorectal Cancer Incidence

Estrogen and colorectal cancer incidence and mortality in the Women's Health Initiative clinical trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3594-3594
Author(s):  
Sayeh Moazami Lavasani ◽  
Rowan T. Chlebowski ◽  
Ross L Prentice ◽  
Ikuko Kato ◽  
Jean Wactawski-Wende ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Waist Circumference ◽  
Cancer Incidence ◽  
Conjugated Equine Estrogen ◽  
Health Initiative ◽  
Increased Risk ◽  
Incidence And Mortality ◽  
Colorectal Cancer Incidence

3594 Background: The preponderance of observational studies associate estrogen alone use with lower colorectal cancer incidence. In contrast, no difference in colorectal cancer incidence was seen in the Women's Health Initiative (WHI) randomized, controlled trial (RCT) of estrogen versus placebo after 7.1 years mean intervention. We now assess the influence of estrogen alone use on longer-term colorectal cancer incidence and mortality after an additional 5.6 years post-intervention follow-up. Methods: The WHI study was a randomized, double-blind, placebo-controlled clinical trial involving 10,739 postmenopausal women who had undergone prior hysterectomy and who were randomly assigned to receive daily 0.625 conjugated equine estrogen (n = 5279) or matching placebo (n = 5409). Colorectal cancer diagnosis rates and mortality were assessed after a mean of 7.1 years (standard deviation [SD] 1.1) of intervention and 12.7 years follow-up. Results: Colorectal cancer incidence in the treatment and control groups were almost equivalent, 0.15% diagnoses/year v 0.13% in the estrogen therapy arm and the placebo group, respectively (Hazard ratio [HR], 1.12; 95% Confidence Interval [CI], 0.83-1.52; P = 0.46). Bowel screening examinations were comparable in both groups throughout. For women age 70-79 at study entry, hormone therapy was associated with an increased risk of colorectal cancer, HR 1.71; 95% CI, (1.02-2.86). For women age 50-59 and 60-69, the respective HR’s and 95% CI were 0.86 (0.43-1.71) and 0.98 (0.64-1.49), p-interaction 0.165. For women with a waist circumference of > 88 cm, there was an increased risk of colorectal cancer, HR 1.53; 95% CI, 0.95-2.45 compared to 0.95 (0.66-1.39) for waist circumference of < 88 cm, p-interaction 0.124. Although not statistically significant, there was a higher number of colorectal cancer deaths in the hormone therapy arm (33 v 24 deaths; 0.05% v 0.04%; HR, 1.42; 95% CI, 0.84-2.41; P = 0.19). Conclusions: There were no significant differences in colorectal cancer incidence or mortality after long-term follow-up in the WHI RCT of conjugated equine estrogen. There was a suggestion of an elevation in colorectal cancer risk among older women randomized to estrogen. Clinical trial information: NCT00000611.

scholarly journals Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis

BMJ Open ◽  
2019 ◽  
Vol 9 (10) ◽  
pp. e032773 ◽  
Author(s):  
Henriette C Jodal ◽  
Lise M Helsingen ◽  
Joseph C Anderson ◽  
Lyubov Lytvyn ◽  
Per Olav Vandvik ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Cancer Screening ◽  
Cancer Incidence ◽  
Cancer Mortality ◽  
Meta Analysis ◽  
Randomised Trials ◽  
Incidence And Mortality ◽  
Colorectal Cancer Incidence ◽  
Colorectal Cancer Mortality

ObjectiveEvaluate effectiveness, harms and burdens of faecal blood testing, sigmoidoscopy and colonoscopy screening for colorectal cancer over 15 years.DesignWe performed an update of a Cochrane systematic review, and performed network meta-analysis comparing randomised trials evaluating colorectal cancer screening with guaiac faecal occult blood test (gFOBT) (annual, biennial), faecal immunochemical test (FIT) (annual, biennial), sigmoidoscopy (once-only) or colonoscopy (once-only) in a healthy population, aged 50–79 years. We conducted subgroup analysis on sex. Follow-up >5 years was required for analysis of colorectal cancer incidence and mortality.Results12 randomised trials proved eligible. Compared with no-screening, we found high certainty evidence for sigmoidoscopy screening slightly reducing colorectal cancer incidence (relative risk (RR) 0.76; 95% confidence interval (CI 0.70 to 0.83) and mortality (RR 0.74; 95% CI 0.69 to 0.80), while gFOBT screening had little or no difference on colorectal cancer incidence, but slightly reduced colorectal cancer mortality (annual: RR 0.69; 95% CI 0.56 to 0.86, biennial: RR 0.88; 95% CI 0.82 to 0.93). No screening test reduced mortality nor incidence by more than six per 1000 screened over 15 years. Sigmoidoscopy had a greater effect in men, for both colorectal cancer incidence (women: RR 0.86; 95% CI 0.81 to 0.92, men: RR 0.75, 95% CI 0.71 to 0.79), and mortality (women: RR 0.85; 95% CI 0.71 to 0.96, men: RR 0.67; 95% CI 0.61 to 0.75) (moderate certainty).ConclusionsIn a 15-year perspective, sigmoidoscopy reduces colorectal cancer incidence, while sigmoidoscopy, annual and biennial gFOBT all reduce colorectal cancer mortality. Sigmoidoscopy may reduce colorectal cancer incidence and mortality more in men than in women.PROSPERO registration numberCRD42018093401.

scholarly journals Colorectal cancer epidemiology: world trends and incidence of colon cancer in the Republic of Uzbekistan in 2012–2017

2020 ◽  
Vol 10 (1) ◽  
pp. 56-63
Author(s):  
S. N. Navruzov ◽  
D. A. Alieva ◽  
E. E. Kulmiev
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Cancer Incidence ◽  
Epidemiological Studies ◽  
Female Ratio ◽  
Global Trends ◽  
Incidence And Mortality ◽  
Colorectal Cancer Incidence ◽  
The Republic ◽  
Male To Female

Objective: epidemiological evaluation of global trends in colorectal cancer and assessment of colon cancer incidence in the Republic of Uzbekistan in 2012–2017.Materials and methods. We used GLOBOCAN data to analyze the situation with colorectal cancer worldwide. We also assessed the incidence of colon cancer, trends, and mean age of patients (by years) registered in the Republic of Uzbekistan. This article emphasizes the need for epidemiological studies of colorectal cancer in Uzbekistan.Results. World trends in colorectal cancer incidence and mortality indicate that these parameters vary across different regions and depend on the economic situation. There are also some sex differences: men are more likely to develop colorectal cancer than women (male to female ratio 1.25:1.0). The number of patient died of colorectal cancer is growing; the male to female ratio is 1.22:1.0.Conclusions. Our assessment of epidemiological situation of colon cancer in the Republic of Uzbekistan demonstrated that its incidence tends to increase, which necessitates further research evaluating regional differences and risk factors for colorectal cancer.

scholarly journals Estrogen Plus Progestin and Colorectal Cancer Incidence and Mortality

2012 ◽  
Vol 30 (32) ◽  
pp. 3983-3990 ◽  
Author(s):  
Michael S. Simon ◽  
Rowan T. Chlebowski ◽  
Jean Wactawski-Wende ◽  
Karen C. Johnson ◽  
Andrew Muskovitz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Hormone Therapy ◽  
Cancer Diagnosis ◽  
Cancer Incidence ◽  
Therapy Group ◽  
Estrogen Plus Progestin ◽  
Colorectal Cancer Incidence ◽  
Colorectal Cancer Mortality

Purpose During the intervention phase in the Women's Health Initiative (WHI) clinical trial, use of estrogen plus progestin reduced the colorectal cancer diagnosis rate, but the cancers were found at a substantially higher stage. To assess the clinical relevance of the findings, analyses of the influence of combined hormone therapy on colorectal cancer incidence and colorectal cancer mortality were conducted after extended follow-up. Patients and Methods The WHI study was a randomized, double-blind, placebo-controlled clinical trial involving 16,608 postmenopausal women with an intact uterus who were randomly assigned to daily 0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate (n = 8,506) or matching placebo (n = 8,102). Colorectal cancer diagnosis rates and colorectal cancer mortality were assessed. Results After a mean of 5.6 years (standard deviation [SD], 1.03 years) of intervention and 11.6 years (SD, 3.1 years) of total follow-up, fewer colorectal cancers were diagnosed in the combined hormone therapy group compared with the placebo group (diagnoses/year, 0.12% v 0.16%; hazard ratio [HR], 0.72; 95% CI, 0.56 to 0.94; P = .014). Bowel screening examinations were comparable between groups throughout. Cancers in the combined hormone therapy group more commonly had positive lymph nodes (50.5% v 28.6%; P < .001) and were at higher stage (regional or distant, 68.8% v 51.4%; P = .003). Although not statistically significant, there was a higher number of colorectal cancer deaths in the combined hormone therapy group (37 v 27 deaths; 0.04% v 0.03%; HR, 1.29; 95% CI, 0.78 to 2.11; P = .320). Conclusion The findings, suggestive of diagnostic delay, do not support a clinically meaningful benefit for combined hormone therapy on colorectal cancer.

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

The Lancet ◽  
2010 ◽  
Vol 376 (9754) ◽  
pp. 1741-1750 ◽  
Author(s):  
Peter M Rothwell ◽  
Michelle Wilson ◽  
Carl-Eric Elwin ◽  
Bo Norrving ◽  
Ale Algra ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Incidence ◽  
Term Effect ◽  
Randomised Trials ◽  
Long Term Effect ◽  
Incidence And Mortality ◽  
Colorectal Cancer Incidence
Sign in / Sign up

Export Citation Format

Share Document